Evidence map›Paper›PMID 22519810›Full record

ArticleAnalytical chemistry2012

High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectrometry.

Xiaotao Duan, Lubna Abuqayyas, Lipeng Dai, Joseph P Balthasar, Jun Qu

Abstract read
In one paragraph

Article in Analytical chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaotao DuanThe Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst, New York 14260, United States.
Lubna Abuqayyas
Lipeng Dai
Joseph P Balthasar
Jun Qu
University at Buffalo, State University of New York · USCenter for Excellence in Education · US

Funding

Pharmacology and bioengineering of new treatments of ITPR01HL067347 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P · 2001 to 2010
$2.5M
FcRn Inhibitors for Antibody-Mediated Immune ConditionsR01AI060687 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P · 2004 to 2007
$1.4M
Pharmacokinetic strategies to optimize IP chemotherapyR01CA118213 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P · 2006 to 2009
$1.0M
Peripheral biomarkers of cocaine dependence and relapseR21DA027528 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI QU, JUN, STRAUBINGER, ROBERT M · 2009 to 2010
$631k
NCI NIH HHS CA118213NCI NIH HHS R01 CA118213NHLBI NIH HHS R01 HL067347NIAID NIH HHS R01 AI060687NIDA NIH HHS DA027528NIDA NIH HHS R21 DA027528
6 · The paper itself

Abstract

Although liquid chromatography/mass spectrometry using selected reaction monitoring (LC/SRM-MS) holds great promise for targeted protein analysis, quantification of therapeutic monoclonal antibody (mAb) in tissues represents a daunting challenge due to the extremely low tissue levels, complexity of tissue matrixes, and the absence of an efficient strategy to develop an optimal LC/SRM-MS method. Here we describe a high-throughput, streamlined strategy for the development of sensitive, selective, and reliable quantitative methods of mAb in tissue matrixes. A sensitive nano-LC/nanospray-MS method was employed to achieve a low lower limit of quantification (LOQ). For selection of signature peptides (SP), the SP candidates were identified by a high-resolution Orbitrap and then optimal SRM conditions for each candidate were obtained using a high-throughput, on-the-fly orthogonal array optimization (OAO) strategy, which is capable of optimizing a large set of SP candidates within a single nano-LC/SRM-MS run. Using the optimized conditions, the candidates were experimentally evaluated for both sensitivity and stability in the target matrixes, and SP selection was based on the results of the evaluation. Two unique SP, respectively from the light and heavy chain, were chosen for quantification of each mAb. The use of two SP improves the quantitative reliability by gauging possible degradation/modification of the mAb. Standard mAb proteins with verified purities were utilized for calibration curves, to prevent the quantitative biases that may otherwise occur when synthesized peptides were used as calibrators. We showed a proof of concept by rapidly developing sensitive nano-LC/SRM-MS methods for quantifying two mAb (8c2 and cT84.66) in multiple preclinical tissues. High sensitivity was achieved for both mAb with LOQ ranged from 0.156 to 0.312 μg/g across different tissues, and the overall procedure showed a wide dynamic range (≥500-fold) and good accuracy [relative error (RE) < 18.8%] and precision [interbatch relative standard deviation (RSD) < 18.1%, intrabatch RSD < 17.2%]. The quantitative method was applied to a comprehensive investigation of the steady-state tissue distribution of 8c2 in wild-type mice versus those deficient in FcRn α-chain, FcγIIb, and FcγRI/FcγRIII, following a chronic dosing regimen. This work represents the first extensive quantification of mAb in tissues by an LC/MS-based method.

Indexed as

Chromatography, High Pressure LiquidMass SpectrometryNanotechnologyAmino Acid SequenceAnimalsAntibodies, MonoclonalDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysMicePeptidesTissue DistributionAntibodies, MonoclonalPeptides

Identifiers

PMID22519810
PMCPMC3352998
OpenAlexW110477109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.